Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3647 Comments
1901 Likes
1
Cappie
Registered User
2 hours ago
This feels like step 0 of something big.
👍 248
Reply
2
Ainsleigh
Active Contributor
5 hours ago
Expert US stock short interest and short squeeze potential analysis for identifying high-risk high-reward opportunities. Our short interest data helps you understand bearish sentiment and potential catalysts for short covering rallies.
👍 250
Reply
3
Lonniesha
Daily Reader
1 day ago
I don’t know why, but this feels urgent.
👍 46
Reply
4
Disaya
Engaged Reader
1 day ago
This feels like step 7 but I missed 1-6.
👍 26
Reply
5
Ruckus
Community Member
2 days ago
Absolutely smashing it today! 💥
👍 293
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.